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Ferrochelatase, the enzyme that catalyzes the terminal
step in the heme biosynthetic pathway, is the site of the
defect in the human inherited disease erythropoietic
protoporphyria. Molecular genetic studies have shown
that the majority of erythropoietic protoporphyria
cases are transmitted in dominant fashion and that
mutations underlying erythropoietic protoporphyria
are heterogeneous. We performed haplotype analysis of
American families that shared recurrent ferrochelatase
gene mutations yet had forebears from several Euro-
pean countries. This was to gain insight into whether
these mutations represent mutational hotspots at the
ferrochelatase gene, or propagation of ancestral alleles
bearing the mutations. Two recurrent mutations were
found to occur on distinctive chromosome 18 haplo-
types, consistent with being hotspot mutations. On
the other hand, we found three sets of two unrelated
families that shared the same haplotypes bearing these
Porphyrias are a heterogeneous group of metabolic errorsthat are chiefly inborn and associated with enzymaticdefects of the heme biosynthetic pathway. Eightenzymes sequentially catalyze the pathway, and withthe exception of the first, partial deficiency of each
leads to a specific form of porphyria. Porphyrias are classified as
either hepatic or erythropoietic, depending on the principal site of
expression of their enzyme defect (Kappas et al, 1995).
Erythropoietic protoporphyria (EPP) is caused by defects of
ferrochelatase (FC, EC. 4.99.1.1), the terminal enzyme of the
pathway, which catalyzes formation of heme by insertion of iron
into protoporphyrin IX. Defective FC leads to accumulations of
protoporphyrin IX in erythrocytes, plasma, and feces. Protoporphy-
rin IX may be deposited in skin by light-induced transfer from red
cells to endothelial cells of dermal capillaries and by interaction
with the ‘‘mitochondrial peripheral-type benzodiazepine’’ receptor,
which binds protoporphyrin tightly, and is found in high levels in
the skin (Smith, 1990). Protoporphyrin IX can be excited by visible
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mutations, which could reflect geographic dispersion
of ancestral mutant alleles. In addition, we report
novel mutations associated with erythropoietic proto-
porphyria: g(F 1)→t transversion of the exon 4 donor
site, g(F 1)→a transition of the exon 6 donor site, and
t(F 2)→a substitution at the exon 9 donor site; these
mutations are predicted to cause splicing defects of
the associated exons. We also identified a g(F 5)→a
transition of the exon 1 donor site in four unrelated
families with erythropoietic protoporphyria, and a
G(– 1)→A substitution at the exon 9 donor site in an
additional family. The probability that these sequence
changes are normal polymorphisms was virtually
excluded (p < 0.0001) by their absence in 120 ferro-
chelatase alleles from 30 normal subjects and 30 indi-
viduals with manifested erythropoietic protoporphyria
with or without a known mutation. Key words: haplotype
analysis, hotspot mutations, porphyrias, splicing mutations.
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light, then react with molecular oxygen to produce reactive oxygen
species that can cause cell damage. Photoexcited protoporphyrin
can also elicit damage by activating the complement system and
degranulating mast cells directly (Todd, 1994). Visible violet light
can penetrate human skin to the level of the upper dermal capillaries,
evoking the immediate cutaneous photosensitivity typically mani-
fested by patients with EPP.
A minority (ø5%–25%) (Todd, 1994) of these patients also
develop liver complications. Protoporphyrin in red cells can diffuse
across the cell membrane and bind to the plasma proteins albumin
and hemopexin. The liver extracts protoporphyrin from the plasma,
and is thought to excrete most of it unchanged into the bile (some
of which is reabsorbed in an enterohepatic circulation), and to
metabolize the remainder. When biliary secretion of protoporphyrin
does not keep pace with the load being presented to the liver,
progressive accumulation of protoporphyrin occurs, causing hepato-
cellular damage that can lead to liver failure (Todd, 1994).
The human FC gene, located on the long arm of chromosome
18, contains a total of 11 exons and 10 introns, and has a minimum
size of about 45 kb. FC cDNA has an open reading frame of
1269 bp encoding a protein of 423 amino acid residues (Nakahashi
et al, 1990; Taketani et al, 1992). Molecular defects underlying EPP
are very heterogeneous; none of the known mutations have so far
been found to occur in high frequency. We identified two recurrent
mutations that were each shared by four unrelated families living
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Table I. Primers in PCR reactions
Region Primers Size Annealing
(bp) temperature
Exon 1 59-GGGGAGCGGGCTTCTAGCTC 416 65°C
59-GGGCGCGAGGGCCCAGGCGC
Exon 4 59-ATCCACTTACCTGTATGT 249 54°C
59-CTTCGAAAGAACTAATCTAG
Exon 6 59-CACCATATCAAATGCATCTAC 232 55°C
59-ACATCCACAAACCCAGAA
Exon 9 59-ACTACAGACCGTCAGAGG 250 58°C
59-GATGGGAAAAAGGCAG
in the United States. Haplotype analysis of the American families
was performed to gain insight into whether their recurrent mutations
represent mutational hotspots in the FC gene, or propagation of
ancestral alleles bearing the mutations. We also report novel
mutations of the FC gene associated with EPP. These observations
enlarge the library of known FC gene mutations and provide new
information elucidating genetic mechanisms responsible for EPP.
MATERIALS AND METHODS
Peripheral blood samples were obtained with informed consent approved
by the Institutional Review Board of St. Luke’s-Roosevelt Hospital Center.
Haplotype analysis All eight families involved in haplotype analysis are
of European ancestries; although there are some common countries of
origin among the forebears of some families, no family is aware of being
related to any of the others.
Haplotype analysis was carried out by using three microsatellite markers,
D18S41 (Straub et al, 1993), D18S858, and D18S977 (J. C. Murray,
personal communication), flanking the FC gene on chromosome 18q22.
These three markers and the FC gene are tightly linked in a region of less
than 2 cM on the sex-averaged linkage map in the order cen–D18S858–
D18S41–FC–D18S977–qtel. The specific primers used for amplification
of these markers were purchased from Research Genetics (Huntsville, AL):
D18S858F: 59-AGCTGGAGAGGGATAGCATT
D18S858R: 59-TGCATTGCATGAAAGTAGGA
D18S41F: 59-CCCTGAAATCATAAGCTCAG
D18S41R: 59-ACACATGATGAACAAGTGACA
D18S977F: 59-CAGTGCTTTGGCTATATCTATCT
D18S977R: 59-TAACCTAGAAAAGGGCACTAGC
The forward primers for these three markers were first end-labeled with
[γ-33P]ATP and then subjected to 30 cycles of polymerase chain reaction
(PCR) at an annealing temperature of 56°C with DNA samples from all
eight families. The PCR products were denatured before being separated
on a polyacrylamide sequencing gel. The banding patterns were visualized
following exposure to X-ray film overnight and genotypes were assigned
by visual inspection in reference to sizing markers run simultaneously.
Mutation analysis Erythrocyte protoporphyrin extraction and assay Erythro-
cyte protoporphyrin was determined by ethyl acetate/acetic acid extraction,
according to a published procedure (Poh-Fitzpatrick et al, 1974).
DNA extraction and PCR DNA template for PCR was prepared as
lysate from whole blood according to a published procedure (Higuchi,
1989). The primers and annealing temperatures used for amplification of
the relevant exons are listed in Table I. PCR conditions for exons 4, 6,
and 9 were as specified by the manufacturer (Perkin Elmer, Branchburg,
NJ). For the exon 1 region, 5% dimethyl sulfoxide was included in the
PCR reaction to achieve satisfactory amplifications. The amplification
profile was 10 min at 95°C for an initial denaturation, followed by 35
cycles at 95°C for 45 s, 54–65°C for 45 s (see Table I for details), 72°C
for 60 s with a final extension at 72°C for 10 min.
Allele-specific oligonucleotide (ASO) hybridization This procedure
was performed essentially as previously described (Saiki et al, 1988), using
radioactive probes. Briefly, amplified products of exons 1 and 9 of the FC
gene were dotted on to nylon filters and then hybridized with 32P-labeled
ASO probes at designated hybridization temperatures (see below). After
hybridization, filters were washed and then exposed to X-OMAT AR film
(Eastman Kodak, Rochester, NY) overnight.
For detecting the transition g(1 5)→a of the exon 1 donor site, ASO
probes E1-N, 59-CCGCGTAAGTGGGTCTG (for binding to the normal
Figure 1. Haplotype analysis. Arrows indicate symptomatic patients.
Black shading with white dots in families A–D represents mutation
1135A→T whereas black shading in families E–H indicates mutation
g(15)→a transition in the exon 1 donor splicing site; checked shading in
family H represents a mis-sense mutation in exon 2. Chromosome 18
haplotypes bearing the two recurrent mutations are shown in boxes;
question mark in family C represents an undetermined allele for a
microsatellite marker; double arrows in family G indicate unassigned
haplotypes. The order of the microsatellite markers is indicated in the
lower left corner.
allele) and E1-M, 59-CCGCGTAAATGGGTCTG (for binding to the
mutant allele, mutant base underlined) were used at a hybridization
temperature of 46°C. For detecting mutation t(1 2)→a of the exon 9 donor
site, ASO probes E9-N, 59-CAAGGAGGTAAATGCAC (for detecting the
normal allele) and E9-M, 59-CAAGGAGGAAAATGCAC (for detecting
VOL. 113, NO. 1 JULY 1999 HAPLOTYPE ANALYSIS IN FAMILIES WITH EPP 89
Table II. Summary of the study
Subjects Erythrocyte protoporphyrin Affected exon Mutation (1/–) Symptom (1/–)
level mean 6 SD (µg per dl)a
Control 43 6 15 (n 5 60)a
Family 1 Proband 1612 6 337 (n 5 3) exon 1 1 1
Mother 38 – –
Father 83 1 –
Family 2 Proband 342 6 55 (n 5 30) exon 1 1 1
Family 3 Proband 1319 6 350 (n 5 28) exon 1 1 1
Mother 158 1 –
Brother 42 – –
Maternal aunt 57 – –
Family 4 Proband 621 6 250 (n 5 5) exon 4 1 1
Family 5 Proband 1449 6 290 (n 5 6) exon 6 1 1
Mother 110 1 –
Father 37 – –
Family 6 Proband 517 6 111 (n 5 5) exon 9 1 1
Mother 80 – –
Father 62 1 –
Sister 48 – –
Brother 1 110 1 1
Brother 2 38 – –
Maternal grandmother 76 – –
Maternal grandfather 47 – –
Paternal grandmother 76 1 –
Paternal grandfather 39 – –
Maternal aunt 64 – –
Family 7 Proband 1945 6 143 (n 5 6) exon 9 1 1
Mother 63 – –
Father 150 1 –
Brother 41 – –
Paternal grandmother 76 1 –
Paternal aunt 68 1 –
aFor control, n 5 number of subjects assayed; for patients, n 5 number of sequential assays for each subject.
Figure 2. Five newly identified splicing mutations in the FC gene.
Upper case, exon sequences; lower case, intron sequences. Shaded letters
highlight the sequence substitutions.
the mutant allele, mutant base underlined) were used at a hybridization
temperature of 50°C.
Heteroduplex analysis/conformation sensitive gel electrophoresis This procedure
was carried out essentially as previously described (Ganguly et al, 1993). A
standard DNA-sequencing gel apparatus was used for the gel electrophoresis.
A 1 mm thick gel was prepared with 8% polyacrylamide with a 99:1 ratio
of acrylamide to 1,4 bis(acryoyl)piperazine (Fluka, Milwaukee, WI), 10%
(vol/vol) ethylene glycol, and 15% (vol/vol) formamide. Amplified DNA
was heated for 8 min at 96°C to denature and was allowed to cool slowly
to permit heteroduplex formation. The samples were then loaded for
overnight electrophoresis at room temperature with a constant voltage of
300 V. The migration patterns were visualized by ethidium bromide
staining after electrophoresis, and when necessary, photographed.
Sequence determination Direct sequencing of PCR products was
done using either an ABI Prism 300 Genetic Analyzer or a 373-A DNA
Sequencer from Applied Biosystems (Perkin Elmer, Forest City, CA). PCR
products were purified using the High Pure PCR Products Purification
Kit (Boehringer Mannheim, Indianapolis, IN) before being processed for
sequencing.
RESULTS
Haplotype analysis Haplotypes bearing 1135A→T mutation (Fig 1,
families A–D) This mutation is a splicing as well as non-sense
mutation originally characterized by us (Wang et al, 1993). Four
families shared this mutation. Haplotype analysis indicated that two
families, A and B, shared one haplotype, [4-5-2], for the mutant
allele. The earliest carrier of the mutation confirmed in the pedigree
of family A is of Irish and Scottish ancestry whereas the earliest
carrier in family B has French, German, and Irish forebears. The
proband of family B has undergone liver transplantation for the
treatment of protoporphyrin-induced hepatic failure (Bloomer et al,
1998). Families C and D, however, were found to share a different
haplotype, [5-4-2], for the mutant allele. The earliest carrier
identified in family C is of Irish extraction whereas those of family
D have forebears from Ireland, Spain, Germany and the Netherlands.
Haplotypes bearing a g→a transition at the 15 position of the exon 1
splicing donor site (Fig 1, families E–H) This novel mutation,
characterized in the Mutation Analysis section of this study, was
identified in four families. Three distinctive haplotypes were found
among these families with families E (earliest carrier of Irish,
English, and unknown other European ancestry) and F (earliest
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Figure 3. Confirmation and screening of family
members for each mutation. Mutations are indicated
by black shading; arrows represent symptomatic
individuals in a family; N/A, not available for testing.
(A) ASO hybridization analysis for mutation g(15)→a
of the exon 1 donor site in families 1–3: lanes 1–3,
family 1; lane 4, family 2; lanes 5–7, family 3. (B) BsiYI
restriction analysis for mutations g(11)→t of the exon
4 donor site and g(11)→a of the exon 6 donor site.
Lanes 1–2, restriction patterns of the exon 4 region:
lane 1, control; lane 2, proband of family 4. Lanes 3–5,
restriction patterns of the exon 6 region in family 5.
(C) MnlI restriction analysis for mutation G(–1)→A of
the exon 9 donor site in family 6. (D) ASO hybridization
analysis for mutation t(12)→a of the exon 9 donor site
in family 7.
carrier of Italian ancestry) sharing the same one, [5-3-1]. The
proband from family H (Italian ancestry) in addition had a mis-
sense mutation in exon 2 that was also identified in her daughter.1
This patient developed myelodysplasia and acute myelogenous
leukemia, and underwent allogenic bone marrow transplant from
her asymptomatic brother.1 As only the proband is available in
family G (Italian ancestry), haplotyping for the mutant allele cannot
be finalized. This haplotype, however, must be distinctive from
the other two because of unique alleles it possesses for markers
D18S858 and D18S977.
Mutation analysis Seven American families (Table II) under-
went mutation analysis. Three of them are represented in the
haplotyping studies described above. Families 1, 2, and 3 of the
mutational studies are families E, G, and F of the haplotyping
studies, respectively. The probands of these families are four males
and three females who currently range in age from 11 to 45 y old.
All had a childhood onset of the painful cutaneous photosensitivity
that is characteristic for EPP; none have manifested evidence of
hepatobiliary disease to date. All of these individuals are Caucasians
of various European ethnic derivations; five have at least some
forebears of Italian origin.
A mutation caused by a g(15)→a transition at the exon 1
donor site Four unrelated families (E–H of the haplotyping
analysis above) shared this transition. The three families from the
Columbia University study group are identified in Fig 2 as families
1–3. The probands of each of these three families were heterozygous
for the mutation. All available family members were screened for
this mutation by ASO hybridization analysis (Fig 3A); the results
are summarized in Table II.
Mutations caused by a g(11)→t transversion at the exon 4 donor site
and by a g(11) a transition at the exon 6 donor site The proband of
family 4 was found to be heterozygous for the g→t transversion at
the 11 position of the exon 4 donor site by sequence determination
(Fig 2, family 4). When the amplified fragments of the exon 6
region of the FC gene were subjected to heteroduplex analysis by
1Lichtin A, Anderson K, Bloomer J, Bolwell B, Poh-Fitzpatrick M,
Wang X: Correction of erythropoietic protoporphyria (EPP) phenotype
by allogenic bone marrow transplantation. Blood 92 (Suppl. 1):523a,
1998 (abstr.)
conformation sensitive gel electrophoresis, the proband of family
5 was found to have a shifted banding pattern compared with
controls, indicating a sequence change in this region (data not
shown). Sequence determination of the exon 6 region showed that
he was heterozygous for a g→a transition at the 11 position of
the exon 6 donor site (Fig 2, family 5). These two mutations
alter restriction patterns; therefore, restriction analysis could be
performed to screen for these mutations among family members
(Fig 3B). Screening results are summarized in Table II.
Mutations caused by a G(–1)→ A transition and a t(12)→a transversion
at the exon 9 donor site Sequencing analysis indicated that the
proband of family 6 bears a G→A transition at the –1 position of
the exon 9 donor site of the FC gene (Fig 2, family 6). This
mutation eliminates a MnlI restriction site. Eleven family members
were screened for this mutation by MnlI digestion (Fig 3C),
revealing that it was transmitted from the paternal grandmother to
the father, then to the proband and his brother. The proband of
family 7 was found to be heteroallelic for a t→a substitution at 12
position of the exon 9 donor site (Fig 2, family 7). ASO
hybridization analysis showed that the mutation was transmitted
from the paternal grandmother to the father, then to the proband
(Fig 3D). Results from restriction analysis and from ASO hybridiza-
tion are shown in Table II.
Table II summarizes the screening results for each mutation
among these seven families with EPP. The presence or absence of
clinical symptoms of EPP for each family member is also noted.
Eight individuals from various families (father of family 1, mother
of family 3, mother of family 5, father and paternal grandmother
of family 6, and father, paternal grandmother, and paternal aunt of
family 7) were found to be positive for mutations. All eight of
them, however, have no photosensitivity and have normal or only
slightly elevated erythrocyte protoporphyrin levels. We consider
these individuals to be asymptomatic mutation carriers.
Thirty control subjects and 30 subjects with manifested EPP
either with or without a known mutation (120 alleles in total),
were screened for these five mutations either by restriction
digestion, ASO hybridization analysis, or direct sequencing.
None were found to be present in any of these 120 alleles.
This argues strongly against the possibility that any of these
novel mutations are normal polymorphisms (binomial test analysis,
p , 0.0001).
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DISCUSSION
The clinical expression of FC gene defects in families with EPP is
often highly variable and detection of asymptomatic mutation
carriers is frequently documented (Gouya et al, 1996; Wang et al,
1997). This is a common phenomenon in porphyrias (Kappas et al,
1995; Deybach et al, 1996; Grandchamp, 1996; Meissner et al,
1996). Our data present eight such asymptomatic carriers for the
five newly characterized mutations (Table II). Why there are so
many silent carriers among families with EPP remains an intriguing
question. Haplotype analysis as performed in this study may provide
an important tool for establishing genetic mechanisms to explain
this phenomenon. In addition to the insight gained by analyzing
haplotypes for mutant alleles as presented above, it is also possible
to draw inferences about the inheritance pattern of EPP from
analysis of the haplotypes of the nonmutant alleles. As shown in
Fig 1, our data revealed that: (i) asymptomatic carriers of the
mutation invariably had different haplotypes for the nonmutant
alleles than did their symptomatic siblings (sister and brother of
family B), and (ii) symptomatic siblings always shared the same
haplotypes for their nonmutant alleles (brothers in family A, brother
and sister in family C, and sisters in family D). These observations
support the hypothesis that a deleterious effect arising from the
nonmutant allele inherited in trans to a mutant allele of the FC
gene may be necessary for full expression of the EPP phenotype
(Went and Klasen, 1984; Gouya et al, 1996).
Although at least three of the earliest identifiable carriers of the
mutation shared by families E–H had full or partial Italian ancestry
in common, their mutations occurred on distinctive chromosome
18 haplotypes, supporting the hypothesis that these genetic errors
are hotspot mutations for EPP. On the other hand, our finding
that unrelated families of diverse European ancestries share the
same haplotypes bearing the same mutation (families A and B, C
and D) could argue in favor of wide geographic dispersion of
ancestral mutant alleles. In family B, however, it cannot be excluded
that the mutation was inherited by its earliest known carrier from
an Irish grandparent who was not available for testing. Similarly in
family D, it is possible that the mutation was inherited from an
Irish forebear rather than Spanish, German, or Dutch ancestors,
none of whom were still living. If so, the sharing of haplotypes
between families A and B, and between families C and D, could
reflect propagation of the mutation within Irish gene pools. In any
case, the results of these haplotyping studies suggest that either
‘‘hotspot’’ or ‘‘dispersed ancestral mutant alleles’’ mechanisms could
explain different instances of recurrent mutations of the FC gene
among apparently unrelated kindreds harboring EPP. Haplotyping
analysis as exemplified here is an informative method that could
be applied to evaluating which mechanism is more likely for other
recurrent mutations.
In general, it is estimated that only about 15% of point mutations
that result in human disease give rise to aberrant splicing (Krawczak
et al, 1992). In EPP, however, about a third of the known mutations
of the FC gene are splicing mutations (Ru¨fenacht et al, 1998). Splice
site consensus sequences are located at intron–exon boundaries on
both sides of an exon; splicing efficiency is critically dependent on
accurate cleavage and ligation at the splice site that appears to be
determined by invariant GT and AG dinucleotides present at the
59 and 39 exon–intron boundaries, respectively (Krawczak et al,
1992). Such conserved dinucleotides were altered in three novel
mutations reported in this study: g(11)→t transversion of the exon
4 donor site, g(11)→a transition of the exon 6 donor site, and
t(12)→a substitution at the exon 9 donor site, and can be predicted
to interfere with normal splicing. Although the g(15)→a transition
at the exon 1 donor site and the G(–1)→A substitution at the exon
9 donor site are changes within the consensus sequence of 59
donor sites, they do not involve one of the consensus conserved
dinucleotides in splicing, so cannot be presumed to be splicing
mutations. It was virtually excluded that they are normal poly-
morphisms, however, as none of them was present in a total of
120 FC alleles from normal persons and other individuals with
EPP. It is also unlikely that a g(15)→a transition in the exon 1
donor site would occur coincidentally as a silent polymorphism in
four unrelated individuals with symptomatic EPP and no other FC
gene mutations. We observed this transition in four of 30 families
with EPP, as contrasted with none of 30 normal control subjects
(p 5 0.0458, Chi-square test of independence). Thus, other
individuals with EPP may well have the same defect. As noted
above, even though three of these families (F, G, and H) have clear
histories of exclusively Italian ancestry in common, their alleles
bearing this transition had three different haplotypes, suggesting
that this site is indeed a ‘‘hotspot’’ for FC gene mutations. In a
previous study, we showed that a g(15)→a transition in the exon
7 donor site caused a splicing error in the FC gene (Wang et al,
1994b), and similar g(15)→a transitions have resulted in mis-
splicing in genes associated with other inherited diseases (Krawczak
et al, 1992).
Mutation of a splicing site can result in one or a combination
of splicing defects. These consist of exon skipping, activation of a
cryptic splice site, and intron retention (Berget, 1995; Maquat,
1996). For the FC gene, when effects of a splice site mutation
have been examined at the cDNA level, the defects have almost
always been exon skipping (Nakahashi et al, 1993a, b; Sarkany et al,
1994a, b; Wang et al, 1994a, b; Gouya et al, 1996; Bloomer et al,
1998). Work toward elucidation of the functional consequences of
the novel mutations described in this study is in progress.
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